GSK Launches New Specialist Unit To Research And Develop Medicines For Rare Diseases

GSK announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases.

Over 5,500 rare diseases have been identified(1) of which less than 10% are currently being treated(2), presenting a significant unmet medical need. Despite the rarity of each condition, the number of diseases means that between 6-8% of the population(3) may be affected by a rare disease. Many are genetic in origin, start in childhood and cause lifelong debility and premature death.

Operating under a lean structure, Marc Dunoyer, GSK’s President of Asia Pacific and Chairman of Japan, will lead this new operation, working closely with Patrick Vallance, GSK’s Senior Vice President of Drug Discovery. The new unit will seek to leverage existing capabilities and partnerships and establish further in-licensing opportunities.

During 2009, GSK entered into strategic collaborations with two specialist companies, Prosensa and JCR Pharmaceuticals.

The alliance with Prosensa, announced in October 2009, focuses on nucleic acid based therapeutics, correcting gene expression in diseases with large unmet medical needs. The scope of the alliance includes four RNA-based compounds intended to treat specific, but different, subpopulations of patients suffering from Duchenne Muscular Dystrophy (DMD).

As part of the agreement with JCR Pharmaceuticals, a Japanese developer and manufacturer of bioactive products, GSK has obtained global rights to a number of enzyme replacement therapies that could, upon approval, be used to treat orphan diseases such as Hunter syndrome, Fabry disease and Gaucher disease.

Marc Dunoyer, GSK’s President of Asia Pacific and Chairman of Japan, said: “In addition to our existing discovery effort, alternative opportunities need to be explored to make treatments available for rare diseases. This complementary approach will combine our existing global expertise with specialist partners .Overtime, this new unit has the potential to deliver multiple therapies responding to high medical needs of underserved populations of patients.”

Patrick Vallance, GSK’s Senior Vice President of Drug Discovery, said: “The entry into this new therapeutic area forms part of GSK’s strategy to deliver more products of value and improve returns in R&D through a focus on areas with a higher probability of success. The risk associated with product discovery and development in rare diseases is generally lower than other disease areas as disease definitions are very clear and clinical trials tend to be small with robust endpoints. In most cases the molecular target is known, making it easier for specialised physicians to diagnose patients”.

GlaxoSmithKline one of the world’s leading research-based pharmaceutical and healthcare companies is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’ s operations are described under ‘Risk Factors’ in the ‘Business Review’ in the company’ s Annual Report on Form 20-F for 2008.

References

(1) http://www.orpha.net; portal for rare diseases and orphan drugs

(2) http://www.fda.gov; analysis of approved therapies (249 in the US since 1983) vs. known rare diseases

(3) “Rare Diseases: Understanding this Public Health Priority.” European Organisation for Rare Diseases, November 2005

Source: GlaxoSmithKline

source : mnt.to

Related News:

• Accelerating The Pace Of Discovery In Cancer Research
• Cordyceps mushroom is an effective cancer treatment, states new research
• Research May Provide Potential Target For New Therapies To Limit Metastasis Of Primary Breast Cancers
• Discovery Of Opposing Functions Of A Key Molecule In The Development Of Organisms Could Benefit Cancer Research
• Agency For Healthcare Research And Quality News And Numbers: High Cholesterol, Diabetes Lead Drug Spending For The Elderly
• Research Identifies New Mechanism Regulating Embryonic Development
• Auxilium Announces Availability Of XIAFLEXTM For The Treatment Of Dupuytren’s Contracture
• Acologix Presents Data On Cartilage Regeneration By AC-100 At The 56th Annual Meeting Of The Orthopaedic Research Society
• COPPERTONE(R) Solar Research Center Unveils Studies On Efficacy Of Topical Antioxidants In Sunscreens At 2010 Annual Meeting
• Eye Condition Linked To Weakened Brain Power In People With Diabetes, Says New Research